Brief: Arcutis Biotherapeutics Says Majority Of Individuals With Co's Atopic Dermatitis Improved Roflumilast Cream 0.15%
14/01/2024 10:41
Jan 14 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* MAJORITY OF INDIVIDUALS WITH ATOPIC DERMATITIS IMPROVED
ROFLUMILAST CREAM 0.15% ACCORDING TO NEW DATA FROM PHASE 3
PROGRAM
* DATA HIGHLIGHT 91.5% OF INDIVIDUALS TREATED WITH
ROFLUMILAST
CREAM HAD MEASURABLE IMPROVEMENT IN ECZEMA AREA AND SEVERITY
INDEX IN 4 WEEKS
* ROFLUMILAST CREAM 0.15% SAFETY AND TOLERABILITY DATA WERE
COMPARABLE WITH VEHICLE, WITH LOW RATES OF APPLICATION SITE
ADVERSE EVENTS
Source text for Eikon: ID:nGNX5MdMq5
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf